Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication attempts to improve sexual desire, increase the number of satisfying sexual events, and decrease the distress associated with low sexual desire. The most common side effects are…
The analysis highlights Community, Culture, Applications and Standards as prominent areas in the source structure around Flibanserin.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Flibanserin shows recurring relationship patterns in the source. For example, Flibanserin → Advisory Committee, Ahead, Boehringer, Boehringer Ingelheim, Complete Response Letter, Drug Administration, FDA, FDA's, Formal Dispute Resolution, III, In December, In June, In October, Sprout, The Agency, The FDA, US Food Another extracted example is Flibanserin → American Sexual Health Association, Association, Black Women's Health Imperative, Congress, Even, Journal, National Consumers League, National Council, National Organization, President, Reproductive Health Professionals, Score, Sexual Medicine, Sprout, Women, Women's Organizations. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
sexual desire fda drug hypoactive us women disorder effects approval serotonin increase medication addyi trials response low 2015 new approved
TTTA extracted 82 structured relationships around Flibanserin. Examples in this analysis include Flibanserin → 3D model (JSmol) → Interactive image and Flibanserin → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Flibanserin | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Flibanserin | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Flibanserin | ATC code | G02CX02 (WHO) | 1.00 | infobox |
| Flibanserin | Bioavailability | 33% | 1.00 | infobox |
| Flibanserin | CAS Number | 167933-07-5 Y | 1.00 | infobox |
| Flibanserin | ChEBI | CHEBI:90865 N | 1.00 | infobox |
| Flibanserin | ChEMBL | ChEMBL231068 Y | 1.00 | infobox |
| Flibanserin | ChemSpider | 5293454 Y | 1.00 | infobox |
| Flibanserin | CompTox Dashboard (EPA) | DTXSID30168445 | 1.00 | infobox |
| Flibanserin | Drug class | Serotonin 5-HT1A receptor partial agonist; Serotonin 5-HT2A receptor antagonist; Dopamine D4 receptor antagonist or very weak partial agonist; Sexual enhancer | 1.00 | infobox |
| Flibanserin | DrugBank | DB04908 | 1.00 | infobox |
| Flibanserin | ECHA InfoCard | 100.170.970 | 1.00 | infobox |
| Flibanserin | Elimination half-life | ~11 hours | 1.00 | infobox |
| Flibanserin | Excretion | Bile duct (51%), kidney (44%) | 1.00 | infobox |
| Flibanserin | Formula | C20H21F3N4O | 1.00 | infobox |
| Flibanserin | IUPHAR/BPS | 8182 | 1.00 | infobox |
| Flibanserin | KEGG | D02577 Y | 1.00 | infobox |
| Flibanserin | Legal status | CA: | 1.00 | infobox |
| Flibanserin | Legal status | US: ℞-only | 1.00 | infobox |
| Flibanserin | License data | US DailyMed: Flibanserin | 1.00 | infobox |
| Flibanserin | MedlinePlus | a615040 | 1.00 | infobox |
| Flibanserin | Metabolism | Extensive by liver (mainly by CYP3A4 and CYP2C19) | 1.00 | infobox |
| Flibanserin | Molar mass | 390.410 g·mol−1 | 1.00 | infobox |
| Flibanserin | Other names | BIMT-17; BIMT17; BIMT-17BS; Girosa; Ectris; Niemunerkeine | 1.00 | infobox |
| Flibanserin | Protein binding | ~98% | 1.00 | infobox |
| Flibanserin | PubChem CID | 6918248 | 1.00 | infobox |
| Flibanserin | Routes of administration | Oral | 1.00 | infobox |
| Flibanserin | Trade names | Addyi, Fliban | 1.00 | infobox |
| Flibanserin | UNII | 37JK4STR6Z | 1.00 | infobox |
The concept neighborhoods around Flibanserin bring nearby vocabulary together. In this analysis, examples include 5-ht1a, Receptor and Low. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Flibanserin, one of the stronger structural bridges in this analysis connects Flibanserin with Mechanism of action. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Flibanserin to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Community, Culture, Applications & Standards, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Flibanserin · EN edition · Analysis: TopicsToTalkAbout